May the force be with you: the power of next-generation sequencing
We know that MRD is relevant, what next?
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
The rise of MRD in multiple myeloma: could this be an answer to a cure?